Phoenix Biotech Acquisition Corp. (NASDAQ: PBAX) is a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. For more information about PBAX, visit www.phoenixbiotechacquisitioncorp.com.
Company profile
Ticker
CERO, PBAXU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OM Merger Sub, Inc. ...
IRS number
871088814
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K/A
Entry into a Material Definitive Agreement
27 Feb 24
D
Exempt offering of security
23 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
25-NSE
Exchange delisting
14 Feb 24
425
Business combination disclosure
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
425
Business combination disclosure
12 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
12 Feb 24
424B3
Prospectus supplement
6 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 119.01 k | 119.01 k | 119.01 k | 119.01 k | 119.01 k | |
Cash burn (monthly) | (no burn) | 32.41 k | 143.27 k | 190.64 k | 16.48 k | |
Cash used (since last report) | n/a | 193.21 k | 854.11 k | 1.14 mm | 98.26 k | |
Cash remaining | n/a | -74.19 k | -735.09 k | -1.02 mm | 20.76 k | |
Runway (months of cash) | n/a | -2.3 | -5.1 | -5.3 | 1.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 4.83 bn |
Total shares | 12.13 mm |
Total puts | 0.00 |
Total calls | 108.75 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Phoenix Biotech Sponsor | 5.30 mm | $0.00 |
Periscope Capital | 957.10 k | $68.53 mm |
Fitzgerald Securities Cantor | 905.00 k | $8.97 mm |
Cantor Fitzgerald, L. P. | 518.55 k | $26.03 mm |
Shaolin Capital Management | 425.00 k | $570.00 k |
MMCAP International Inc. SPC | 375.00 k | $26.85 mm |
Polar Asset Management Partners | 300.00 k | $21.48 mm |
Saba Capital Management | 295.91 k | $22.68 mm |
Linden Advisors | 250.00 k | $19.18 mm |
CNH Partners | 246.70 k | $17.66 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Atwood Brian G | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 1,317,956 | 2.33 mm | 1,317,956 |
25 Mar 24 | Michael Byrnes | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 112,500 | 199.13 k | 112,500 |
25 Mar 24 | Charles Ross Carter | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 395,387 | 699.83 k | 395,387 |
25 Mar 24 | Daniel Corey | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 856,671 | 1.52 mm | 856,671 |
25 Mar 24 | Laporte Kathleen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 112,500 | 199.13 k | 112,500 |
News
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
20 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
US Stocks Down; Dow Falls 100 Points
11 Mar 24
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
11 Mar 24
Press releases
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
8 Mar 24
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
7 Mar 24
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
14 Feb 24